Clinical problems with oral anticoagulant treatment - Three case reports;Praktische probleme mit der oralen antikoagulation - Drei fallbeispiele

Therapeutische Umschau

Volumn 60, Issue 1, 2003, Pages 63-66

  Lammle B ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 9; CARBASALATE CALCIUM; COUMARIN; ETHAMBUTOL; ISONIAZID; PHENPROCOUMON; PHENYLBUTAZONE; PHYTOMENADIONE; PYRAZINAMIDE; RIFAMPICIN; RIFATER;

ADULT; AGED; BLEEDING; CASE REPORT; GENETIC PREDISPOSITION; HUMAN; INTERNATIONAL STANDARD UNIT; REVIEW;

EID: 0037254801     PISSN: 00405930     EISSN: None     Source Type: Journal    
DOI: 10.1024/0040-5930.60.1.63     Document Type: Review

References (17)

1. Chu K, Wu SM, Stanley T, Stafford DW, High KA. A mutation in the propeptide of factor IX leads to warfarin sensitivity by a novel mechanism. J Clin Invest 1996; 98: 1619-25.
2. Oldenburg J, Quenzel EM, Harbrecht U, et al. Missense mutation at Ala-10 in the factor IX-propeptide: an insignificant variant in normal life but a decisive cause for bleeding during oral anticoagulant therapy. Br J Haematol 1997; 98: 240-4.
3. Quenzel EM, Hertfelder HJ, Oldenburg J. Severe bleeding in two patients due to increased sensitivity of factor IX activity to phenprocoumon therapy. Ann Hematol 1997; 74: 265-8.
4. Oldenburg J, Kriz K, Wuillemin WA, et al. Genetic predisposition to bleeding during oral anticoagulant therapy: Evidence for common founder mutations (FIX Val-10 and FIX Thr-10) and an independent CpG hotspot mutation (FIX Thr-10). Thromb Haemost 2001; 85: 454-7.
5. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet 1996; 348: 423-8.
6. Levine MN, Raskob G, Landefeld S, Kearon C. Hemorrhagic complications of anticoagulant treatment. Chest 2001; 119: 108S-121S.
7. Broekmans AW, Bertina RM, Loeliger EA, Hofmann V, Klingemann HG. Protein C and the development of skin necrosis during anticoagulant therapy. Thromb Haemost 1983; 49: 244.
8. Wuillemin WA, Zenhäusern R, Bernhard MC, Lämmle B. Phenprocoumon-induced hepatitis delaying precise diagnosis in a thrombophilic patient with activated protein C resistance due to factor V R506Q mutation. Am J Med 1997; 103: 437-9.
9. Iturbe-Alessio I, del Carmen Fonseca M, Mutchinik O, Santos MA, Zajarias A, Salazar E. Risks of anticoagulant therapy in pregnant women with artificial heart valves. N Engl J Med 1986; 315: 1390-3.
10. Hirsh J. Oral anticoagulant drugs. N Engl J Med 1991; 324: 1865-75.
11. Lämmle B, Hardegger T, Straub PW, Vock P, Furlan M. Die innere Blutung beim oral antikoagulierten Patienten. Schweiz med Wochenschr 1993; 123: 701-10.
12. Hull R, Delmore T, Genton E, et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med 1979; 301: 855-8.
13. Hull R, Delmore T, Carter C, et al. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med 1982; 306: 189-94.
14. Hull R, Hirsh J, Jay R, et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med 1982; 307: 1676-81.
15. Hirsh J, Levine M. Confusion over the therapeutic range for monitoring oral anticoagulant therapy in North America. Thromb Haemost 1988; 59: 129-32.
16. Haemostasis and Thrombosis Task Force for the British Committee for Standards in Haematology. Guidelines on oral anticoagulation: third edition. Br J Haematol 1998; 101: 374-87.
17. Hirsh J, Dalen JE, Anderson DR, et al. Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001; 119: 8S-21S.